Comparison of Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
A Double-Blind, Randomized Study Comparing Intramuscular Olanzapine Depot With Placebo in the Treatment of Patients With Schizophrenia
Sponsor: Eli Lilly and Company
Listed as NCT00088478, this PHASE3 trial focuses on Schizophrenia and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baltimore, United States, Beachwood, United States, Bradenton, United States, Chagrin Falls, United States, Chicago, United States, Clementon, United States, Columbia, United States, Denver, United States, Hoffman Estates, United States, Honolulu, United States and 26 more location s